Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Comparison of the Eight-Hour With the 22-Hour Infusion of 5-Fluorouracil, in the FOLFOX Chemotherapy of Colon Cancer: A Retrospective Study

Hodjatollah Shahbazian 1 , Sasan Razmjoo 1 , Shoale Arvandi 1 , Seyed Mohammad Hosseini 2 , Mehran Hoseinzadeh 3 , Ahmad Ahmadzadeh Deilamani 3 and Fatemeh Mohammadian 1 , *
Authors Information
1 Department of Clinical Oncology, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
2 Cancer, Petroleum and Environmental Pollutants Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
3 Department of Hematology and Medical Oncology, Shafa Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: May 01, 2016, 11 (2); e30674
  • Published Online: April 18, 2016
  • Article Type: Research Article
  • Received: June 27, 2015
  • Revised: August 6, 2015
  • Accepted: August 25, 2015
  • DOI: 10.17795/jjnpp-30674

To Cite: Shahbazian H, Razmjoo S, Arvandi S, Hosseini S M, Hoseinzadeh M, et al. Comparison of the Eight-Hour With the 22-Hour Infusion of 5-Fluorouracil, in the FOLFOX Chemotherapy of Colon Cancer: A Retrospective Study, Jundishapur J Nat Pharm Prod. 2016 ; 11(2):e30674. doi: 10.17795/jjnpp-30674.

Abstract
Copyright © 2016, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Lin YL, Liang JT. FOLFOX4 in the adjuvant treatment of colon cancer in Asian patients. Hepatogastroenterology. 2012; 59(114): 400-4[DOI][PubMed]
  • 2. Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015; 14(1): 1-10[DOI][PubMed]
  • 3. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27(19): 3109-16[DOI][PubMed]
  • 4. Saini A, Norman AR, Cunningham D, Chau I, Hill M, Tait D, et al. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer. 2003; 88(12): 1859-65[DOI][PubMed]
  • 5. Chau I, Norman AR, Cunningham D, Tait D, Ross PJ, Iveson T, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol. 2005; 16(4): 549-57[DOI][PubMed]
  • 6. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol. 2005; 23(20): 4553-60[DOI][PubMed]
  • 7. El-Khoueiry AB, Lenz HJ. Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe? Cancer Invest. 2006; 24(1): 50-5[DOI][PubMed]
  • 8. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989; 7(4): 425-32[PubMed]
  • 9. Chau I, Norman AR, Cunningham D, Iveson T, Hill M, Hickish T, et al. Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. Eur J Cancer. 2005; 41(11): 1551-9[DOI][PubMed]
  • 10. Anderson N, Lokich J. Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparisons. Cancer. 1992; 70(4 Suppl): 998-1002[PubMed]
  • 11. Andre T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Curr Colorectal Cancer Rep. 2013; 9: 261-9[DOI][PubMed]
  • 12. Chu E, Haller D, Cartwright T, Twelves C, Cassidy J, Sun W, et al. Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial. Br J Cancer. 2014; 110(6): 1438-45[DOI][PubMed]
  • 13. Kriza C, Emmert M, Wahlster P, Niederlander C, Kolominsky-Rabas P. Cost of illness in colorectal cancer: an international review. Pharmacoeconomics. 2013; 31(7): 577-88[DOI][PubMed]
  • 14. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16): 2938-47[PubMed]
  • 15. Schilsky RL. Biochemical and clinical pharmacology of 5-fluorouracil. 1998; : 13-8
  • 16. Thrall MM, Wood P, King V, Rivera W, Hrushesky W. Investigation of the comparative toxicity of 5-FU bolus versus 5-FU continuous infusion circadian chemotherapy with concurrent radiation therapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2000; 46(4): 873-81[DOI]
  • 17. Takimoto CH, Yee LK, Venzon DJ, Schuler B, Grollman F, Chabuk C, et al. High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion. Clin Cancer Res. 1999; 5(6): 1347-52[PubMed]
  • 18. Di Paolo A, Lencioni M, Amatori F, Di Donato S, Bocci G, Orlandini C, et al. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Clin Cancer Res. 2008; 14(9): 2749-55[DOI][PubMed]
  • 19. Smaaland R, Laerum OD, Lote K, Sletvold O, Sothern RB, Bjerknes R. DNA synthesis in human bone marrow is circadian stage dependent. Blood. 1991; 77(12): 2603-11[PubMed]
  • 20. Buchi KN, Moore JG, Hrushesky WJ, Sothern RB, Rubin NH. Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology. 1991; 101(2): 410-5[PubMed]
  • 21. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 1990; 50(1): 197-201[PubMed]
  • 22. Harris BE, Song RL, He YJ, Soong SJ, Diasio RB. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy. Biochem Pharmacol. 1988; 37(24): 4759-62[DOI]
  • 23. Zhang R, Lu Z, Liu T, Soong SJ, Diasio RB. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res. 1993; 53(12): 2816-22[PubMed]
  • 24. Petit E, Milano G, Levi F, Thyss A, Bailleul F, Schneider M. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res. 1988; 48(6): 1676-9[PubMed]
  • 25. Fleming GF, Schumm P, Friberg G, Ratain MJ, Njiaju UO, Schilsky RL. Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. BMC Cancer. 2015; 15: 69[DOI][PubMed]
  • 26. Levi F, Focan C, Karaboue A, de la Valette V, Focan-Henrard D, Baron B, et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev. 2007; 59(9-10): 1015-35[DOI][PubMed]
  • 27. Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst. 2009; 101(22): 1543-52[DOI][PubMed]
  • 28. Innominato PF, Roche VP, Palesh OG, Ulusakarya A, Spiegel D, Levi FA. The circadian timing system in clinical oncology. Ann Med. 2014; 46(4): 191-207[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments